Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Gross Profit of $54.2 million for Q1 2026, up 10.81% year-over-year from $48.9 million in Q1 2025, and down 15.09% quarter-over-quarter from $63.8 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $54.2 million for Q1 2026.
- In Q1 2026, Gross Profit rose 10.81% year-over-year to $54.2 million; the TTM figure through Mar 2026 stood at $279.9 million (up 53.78% YoY), while the FY2025 annual figure was $274.7 million, up 70.99% from the prior year.
- Gross Profit for Q1 2026 stood at $54.2 million, down from $63.8 million in the prior quarter.
- The five-year high for Gross Profit was $97.2 million in Q2 2025, with the low at $16.6 million in Q1 2022.
- The 5-year median for Gross Profit is $34.0 million (2024), against an average of $42.2 million.
- The sharpest annual moves came in 2022 and 2025: Gross Profit tumbled 79.41% in 2022, then soared 185.54% in 2025.
- Rigel Pharmaceuticals' Gross Profit stood at $50.9 million in 2022, then tumbled by 37.17% to $32.0 million in 2023, then surged by 61.89% to $51.8 million in 2024, then grew by 23.24% to $63.8 million in 2025, then declined by 15.09% to $54.2 million in 2026.
- Business Quant data shows RIGL's Gross Profit at $54.2 million in Q1 2026, $63.8 million in Q4 2025, and $64.7 million in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|